GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Additional Paid-In Capital : ₦51 Mil(As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Additional Paid-In Capital?

GlaxoSmithKline Consumer Nigeria's quarterly additional paid-in capital stayed the same from Sep. 2022 (₦51 Mil) to Dec. 2022 (₦51 Mil) and stayed the same from Dec. 2022 (₦51 Mil) to Jun. 2023 (₦51 Mil).

GlaxoSmithKline Consumer Nigeria's annual additional paid-in capital stayed the same from Dec. 2020 (₦51 Mil) to Dec. 2021 (₦51 Mil) and stayed the same from Dec. 2021 (₦51 Mil) to Dec. 2022 (₦51 Mil).

GlaxoSmithKline Consumer Nigeria Additional Paid-In Capital Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Additional Paid-In Capital Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

51.40

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															51.40	51.40	51.40	51.40	51.40

GlaxoSmithKline Consumer Nigeria Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

GlaxoSmithKline Consumer Nigeria Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines